AbbVie’s Maviret, known as Mavyret (glecaprevir/pibrentasvir) in the U.S., just became the only therapy approved in the EU for both acute and chronic hepatic C virus (HCV) , removing the need to confirm chronicity before treatment. While 2020 clinical guidance already recommended prompt treatment for acute HCV, the drug’s previous chronic-only indication could still lead to additional documentation, reimbursement hurdles or delays.The expanded indication brings the drug’s approved use in line with existing clinical recommendations. “We no longer have to…